Table 4 Responses for ‘knowledge needed’ (N (%) responses) for all responses that relate to knowledge needed)
Nodes | Sub-nodes | Sub-sub-node | e-learning module (N = 188) | Site visits (N = 85) | Barriers & Facilitators Survey (N = 65) |
|---|---|---|---|---|---|
Mechanism of action | 11 (5.9Â %) | 2 (2.4Â %) | 17 (26.2Â %) | ||
 Administration | Overall | 47 (25.0 %) | 61 (71.8 %) | 26 (40.0 %) | |
 Transfer | 0 | 2 | 0 | ||
 Threatened preterm labour vs. imminent preterm birth | 3 | 10 | 0 | ||
 Timing of administration | 6 | 9 | 7 | ||
 Standards of practice | 4 | 10 | 2 | ||
 Re-treatment | 0 | 7 | 3 | ||
 Pre-printed orders | 1 | 0 | 0 | ||
 Policies and protocols | 8 | 3 | 7 | ||
 Multiple pregnancies | 1 | 0 | 0 | ||
 Gestational age | 8 | 7 | 2 | ||
 Drug interactions | 5 | 0 | 0 | ||
 Contraindications | 1 | 2 | 0 | ||
 Unclassified | 10 | 11 | 5 | ||
 Side effects and risks | Overall | 26 (13.8 %) | 16 (18.8 %) | 6 (9.2 %) | |
 Rapid delivery | 1 | 0 | 0 | ||
 Overuse | 1 | 1 | 0 | ||
 Interventions as a result of MgSO4 | 3 | 0 | 0 | ||
 Increased monitoring needed | 5 | 0 | 0 | ||
 Adverse physiological effects – neonate |  Toxicity | 3 | 1 | 0 | |
|  |  Problems with feeding | 1 | 0 | 0 | |
|  |  Neonatal respiratory depression | 6 | 3 | 0 | |
|  |  Long-term effects | 0 | 1 | 2 | |
|  |  Adverse neurological effects | 1 | 0 | 0 | |
 Adverse physiological effects – general (unspecified maternal/neonate) | 0 | 7 | 0 | ||
 Unclassified | 4 | 2 | 4 | ||
 KT tools | Overall | 7 (3.7 %) | 0 | 3 (4.6 %) | |
 Audit and feedback | 1 | 0 | 0 | ||
 Unclassified | 6 | 0 | 3 | ||
 Research | Overall | 46 (24.5 %) | 5 (5.9 %) | 13 (20.0 %) | |
 Further research | 33 | 3 | 5 | ||
 Evidence to date | 6 | 1 | 7 | ||
 Unclassifiable | 7 | 1 | 1 | ||
 Other uses and topics (not MgSO4 for fetal neuroprotection) | 30 (16.0 %) | 1 (1.2 %) | 0 | ||
 None stated | 21 (11.2 %) | 0 | 0 | ||